<strong>PCOS Is Getting a Rebrand—and It Makes a Big Difference, Experts Say</strong>

Reported by Women's Health Magazine.

One letter. That's all that separates PCOS from PMOS—but according to Women's Health Magazine, that single-letter shift represents one of the most significant reframes in reproductive endocrinology in recent memory. Polycystic ovarian syndrome is officially being retired; polyendocrine metabolic syndrome is its replacement. The rename wasn't arbitrary: it's the result of a decade-long effort led by endocrinologist Helena Teede, PhD, of Monash University, drawing on input from more than 50 organizations and over 22,000 patients and clinicians globally. The findings were published in The Lancet this week, making the change official.

The old name was doing real damage. "It was fundamentally incorrect," says Teede. PCOS implied abnormal ovarian cysts—which many people with the condition don't actually have—and framed the syndrome as a gynecological issue when it is, in fact, a full-body metabolic and hormonal one. Between 70 and 80 percent of people with the syndrome have insulin resistance, notes OBGYN and reproductive endocrinologist Lora Shahine, MD, of Pacific Northwest Fertility. Add to that elevated rates of hypertension, dyslipidemia, sleep apnea, and a four-fold increased risk of type 2 diabetes (per the WHO), and you start to see how badly the ovary-centric framing was underselling the condition. "For the patients I see every day, this condition is so much bigger than that," says endocrinologist Rekha Kumar, MD, of NewYork-Presbyterian Hospital.

The Cost of Getting the Name Wrong

Up to 70 percent of people with PMOS remain undiagnosed—and the misleading name is a direct contributor. When clinicians focused exclusively on ovarian or reproductive symptoms, they missed metabolic red flags hiding in plain sight. Patients, meanwhile, were handed birth control prescriptions or told to lose weight, with no one connecting the dots to what was actually happening hormonally. "Insulin resistance, chronic inflammation, fatigue, weight changes—these were too often treated as secondary concerns or, worse, as personal failures," Dr. Kumar says. A teenager with acne and irregular cycles should be getting a metabolic workup, Dr. Shahine argues—not just a pill. And a woman in perimenopause should still have her cardiovascular health tracked, because those risks don't disappear when ovulation does.

The rename reframes the standard of care entirely. Going forward, PMOS should be treated as a multidisciplinary condition—primary care, endocrinology, cardiology, mental health, and reproductive medicine all have a role. "The new name is a prompt," Dr. Shahine says. "It signals at every encounter that this is an endocrine and metabolic condition, not just a gynecologic one." There's also a cultural dimension: primary care physician and Women's Health Advisory Board member Navya Mysore, MD, notes that the shift is validating for patients who spent years being dismissed. OBGYN Kelly Culwell, MD, adds that conditions perceived as "women's issues" are chronically underfunded—a more accurate, systemic name could help PMOS finally get the research attention it deserves.

The rename is a meaningful start, but Teede is clear-eyed about what still needs to follow: reclassification in clinical systems, updated payer policies, research in underrepresented populations, and a cultural overhaul in how medicine talks about women's metabolic health. A more accurate name is only as powerful as the care infrastructure built around it.

Read the original at Women's Health Magazine.